Xianying Li

Jining, 272000, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Corrigendum to 'Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response' (J Hepatol 2025 [946-958]).

Corrigendum to 'Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response' (J Hepatol 2025 [946-958]).

Journal: Journal of hepatology
Published: October 28, 2025

Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma.

Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma.

Journal: Journal of experimental & clinical cancer research : CR
Published: April 16, 2025

m6A epitranscriptomic modification in hepatocellular carcinoma: implications for the tumor microenvironment and immunotherapy.

m6A epitranscriptomic modification in hepatocellular carcinoma: implications for the tumor microenvironment and immunotherapy.

Journal: Frontiers in immunology
Published: December 03, 2024

Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response.

Tumor-derived CD109 orchestrates reprogramming of tumor-associated macrophages to dampen immune response.

Journal: Journal of hepatology
Published: July 08, 2024

Cholangiocarcinoma PDHA1 succinylation suppresses macrophage antigen presentation via alpha-ketoglutaric acid accumulation.

Cholangiocarcinoma PDHA1 succinylation suppresses macrophage antigen presentation via alpha-ketoglutaric acid accumulation.

Journal: Nature communications
Published: July 02, 2024

Hepatocellular Carcinoma LINC01116 Outcompetes T Cells for Linoleic Acid and Accelerates Tumor Progression.

Hepatocellular Carcinoma LINC01116 Outcompetes T Cells for Linoleic Acid and Accelerates Tumor Progression.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: January 18, 2024

A STT3A-dependent PD-L1 glycosylation modification mediated by GMPS drives tumor immune evasion in hepatocellular carcinoma.

A STT3A-dependent PD-L1 glycosylation modification mediated by GMPS drives tumor immune evasion in hepatocellular carcinoma.

Journal: Cell death and differentiation
Published: January 16, 2024

LncRNA PWRN1 inhibits the progression of hepatocellular carcinoma by activating PKM2 activity.

LncRNA PWRN1 inhibits the progression of hepatocellular carcinoma by activating PKM2 activity.

Journal: Cancer letters
Published: August 06, 2023

Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors.

Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors.

Journal: Nature communications
Published: June 29, 2023

LncRNA CRNDE Drives the Progression of Hepatocellular Carcinoma by inducing the Immunosuppressive Niche.

LncRNA CRNDE Drives the Progression of Hepatocellular Carcinoma by inducing the Immunosuppressive Niche.

Journal: International journal of biological sciences
Published: April 20, 2023

Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib.

Targeting SLP2-mediated lipid metabolism reprograming restricts proliferation and metastasis of hepatocellular carcinoma and promotes sensitivity to Lenvatinib.

Journal: Oncogene
Published: June 17, 2022

Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.

Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.

Journal: Journal of hepatology
Published: March 22, 2022
Showing 1-12 of 15

Last Updated: 09/26/2026